Moderna Highlights Respiratory Product Pipeline at JP Morgan Healthcare Conference

Moderna’s vaccine revenue dropped from $18.4 billion in 2022 to $6.7 billion in 2023, however the company anticipates profitability this year powered by COVID-19 vaccine sales and the launch of its mRNA-based respiratory syncytial virus vaccine.

Source link
#Moderna #Highlights #Respiratory #Product #Pipeline #Morgan #Healthcare #Conference